Brand-name prescription drug prices have doubled in the last five years, according to a new report. Now some public health groups and organizations say things could get worse, if the Trans-Pacific Partnership deal delays the introduction of generic drugs. RT America’s Ed Schultz speaks with Lori Wallach, director of Public Citizen’s Global Trade Watch, about how the new deal could lead to even higher costs of medication.
Pharma companies use TPP to extend their monopolies (Video)
